Skip to main content
Disciplines
Automotive Business IT + Informatics Construction + Real Estate Electrical Engineering + Electronics Energy + Sustainability Insurance + Risk Finance + Banking Management + Leadership Marketing + Sales Mechanical Engineering + Materials
Events
DE
EN
Books
Journals
Topic Page
Marketing
Start single access now
Access for companies
EXTENDED SEARCH
Log in
Top
Published in:
Development of a Manufacturing Process for the Formation of a Nucleoside Drug Candidate Read chapter Read first chapter

2016 | OriginalPaper | Chapter

Story of Eribulin Mesylate: Development of the Longest Drug Synthesis

Author : Armin Bauer

Published in: Synthesis of Heterocycles in Contemporary Medicinal Chemistry

Publisher: Springer International Publishing

Log in

Activate our intelligent search to find suitable subject content or patents.

search-config
loading …

Abstract

Eribulin mesylate (Halaven™), approved in 2010 as an anticancer agent, represents a simplified analogue of the marine natural product halichondrin B, which was isolated in 1986 from the sea sponge Halichondria okadai. The story of the discovery, development, and launch of this drug impressively demonstrates how far the limits of total synthesis of natural products have been pushed today on an industrial scale since it can be considered the most complex synthetic drug today.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

inform now

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

inform now
previous chapter Development of Synthetic Routes to Dolutegravir
Literature
1.
2.
Tachibana K, Scheuer PJ, Tsukitani Y, Kikuchi H, Van Engen D, Clardy J, Gopichand Y, Schmitz FJ (1981) J Am Chem Soc 103:2469–2471CrossRef
3.
4.
Yamamoto A, Ueda A, Brémond P, Tiseni PS, Kishi Y (2012) J Am Chem Soc 134:893–896CrossRef
5.
Pettit GR, Tan R, Gao F, Williams MD, Doubek DL, Boyd MR, Schmidt JM, Chapuis J-C, Hamel E, Bai R, Hooper JNA, Tackett LP (1993) J Org Chem 58:2538–2543CrossRef
6.
Litaudon M, Hart JB, Blunt JW, Lake RJ, Munro MHG (1994) Tetrahedron Lett 35:9435–9438CrossRef
7.
Litaudon M, Hickford SJH, Lill RE, Lake RJ, Blunt JW, Munro MHG (1997) J Org Chem 62:1868–1871CrossRef
8.
9.
Pettit GR, Herald CL, Boyd MR, Leed JE, Dufresne C, Doubek DL, Schmidt JM, Cerny RL, Hooper JNA, Rützler KC (1991) J Med Chem 34:3339–3340CrossRef
10.
11.
Bai R, Paull KD, Heraldy CL, Malspeis L, Pettit GR, Hamel E (1991) J Biol Chem 266:15882–15889
12.
Ludueña RF, Roach MC, Prasad V, Pettit GR (1993) Biochem Pharmacol 45:421–427CrossRef
13.
Dabydeen D, Burnett JC, Bai R, Verdier-Pinard P, Hickford SJH, Pettit GR, Blunt JW, Munro MHG, Gussio R, Hamel E (2006) Mol Pharmacol 70:1866–1875CrossRef
14.
Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L (2005) Mol Cancer Ther 4:1086–1095CrossRef
15.
16.
Yu MJ, Zheng W, Seletsky BM, Littlefield BA, Kishi Y (2011) Annu Rep Med Chem 46:227–241CrossRef
17.
Munro MHG, Blunt JW, Dumdei EJ, Hickford SJH, Lill RE, Li S, Battershill CN, Duckworth AR (1999) J Biotechnol 70:15–25CrossRef
18.
Aicher TD, Buszek KR, Fang FG, Forsyth CJ, Jung SH, Kishi Y, Matelich MC, Scola PM, Spero DM, Yoon SK (1992) J Am Chem Soc 114:3162–3164CrossRef
19.
Yu MJ, Kishi Y, Littlefield BA (2012) Discovery of E7389, a fully synthetic macrocyclic ketone analog of halichondrin B. In: Cragg GM, Kingston DGI, Newman DJ (eds) Anticancer agents from natural products, 2nd edn. CRC Press, Boca Raton, pp 317–345
20.
Jackson KL, Henderson JA, Motoyoshi H, Philips AJ (2009) Angew Chem Int Ed 48:2346–2350CrossRef
21.
22.
23.
Towle MJ, Salvato KA, Wels BF, Aalfs KK, Zheng W, Seletsky BM, Zhu X, Lewis BM, Kishi Y, Yu MJ, Littlefield BA (2011) Cancer Res 71:496–505CrossRef
24.
Wang Y, Habgood GJ, Christ WJ, Kishi Y, Littlefield BA, Yu MJ (2000) Bioorg Med Chem Lett 10:1029–1032CrossRef
25.
Seletsky BM, Wang Y, Hawkins LD, Palme MH, Habgood GJ, DiPietro LV, Towle MJ, Salvato KA, Wels BF, Aalfs KK, Kishi Y, Littlefield BA, Yu MJ (2004) Bioorg Med Chem Lett 14:5547–5550CrossRef
26.
Zheng W, Seletsky BM, Palme MH, Lydon PJ, Singer LA, Chase CE, Lemelin CE, Shen Y, Davis H, Tremblay L, Towle MJ, Salvato KA, Wels BF, Aalfs KK, Kishi Y, Littlefield BA, Yu MJ (2004) Bioorg Med Chem Lett 14:5551–5554CrossRef
27.
Towle MJ, Salvato KA, Budrow J, Wels BF, Kuznetsov G, Aalfs KK, Welsh S, Zheng W, Seletsky BM, Palme MH, Habgood GJ, Singer LA, DiPietro LV, Wang Y, Chen JJ, Quincy DA, Davis A, Yoshimatsu K, Kishi Y, Yu MJ, Littlefield BA (2001) Cancer Res 61:1013–1021
28.
29.
30.
Littlefield BA, Palme M, Seletsky BM, Towle MJ, Yu MJ (1999) Macrocyclic analogs and methods of their use and preparation. PCT Int Appl WO 99/65894, 23 Dec 1999
31.
Littlefield BA, Palme MH, Seletsky BM, Towle MJ, Yu MJ, Zheng W (2001) Macrocyclic analogs and methods of their use and preparation. US Patent 6,214,865, 10 April 2001
32.
33.
34.
Kishi Y, Fang FG, Forsyth CJ, Scola PM, Yoon SK (1995) Synthesis of halichondrin B and norhalichondrin B. US Patent 5,436,238, 25 July 1995
35.
36.
Smith AB, Chen SSY, Nelson FC, Reichert JM, Salvatore BA (1995) J Am Chem Soc 117:12013–12014CrossRef
37.
38.
39.
Littlefield BA, Palme MH, Seletsky BM, Towle MJ, Yu MJ, Zheng W (2002) Intermediate compounds for preparing macrocyclic analogs. US Patent 6,365,759, 2 April 2002
40.
Wan ZK, Choi H, Kang FA, Nakajima K, Demeke D, Kishi Y (2002) Org Lett 25:4431–4434CrossRef
41.
Austad B, Chase CE, Fang FG (2005) Intermediates for the preparation of halichondrin B. PCT Int Appl WO 2005/118565, 15 Dec 2005
42.
Choi H, Nakajima K, Demeke D, Kang FA, Jun HS, Wan ZK, Kishi Y (2002) Org Lett 25:4435–4438CrossRef
43.
Hu Y (2009) Halichondrin B analogs. PCT Int Appl WO 2009/124237, 8 Oct 2009
44.
Austad BC, Calkins TL, Chase CE, Fang FG, Horstmann TE, Hu Y, Lewis BM, Niu X, Noland TA, Orr JD, Schnaderbeck MJ, Zhang H, Asakawa N, Asai N, Chiba H, Hasebe T, Hoshino Y, Ishizuka H, Kajima T, Kayano A, Komatsu Y, Kubota M, Kuroda H, Miyazawa M, Tagami K, Watanabe T (2013) Synlett 24:333–337CrossRef
45.
Chiba H, Fukuyama T, Takigawa T, Komatsu Y (2012) Microreactor process for halichondrin B analog synthesis. PCT Int Appl WO 2012/147900, 1 Nov 2012
46.
Hu Y, Zhang H, Chiba H, Komatsu Y (2015) Methods useful in the synthesis of halichondrin B analogs. PCT Int Appl WO 2015/085193, 11 June 2015
47.
Fukuyama T, Chiba H, Kuroda H, Takigawa T, Kayano A, Tagami K (2016) Org Process Res Dev 20:503–509
48.
Inanga K, Fukuyama T, Kubota M, Komatsu Y, Chiba H, Kayano A, Tagami K (2015) Org Lett 17:3158–3161CrossRef
49.
Chase CE, Fang F, Lewis BM, Wilkie GD, Schnaderbeck MJ, Zhu X (2013) Synlett 24:323–326CrossRef
50.
51.
Tokunaga M, Larrow JF, Kakiuchi F, Jacobsen EN (1997) Science 277:936–938CrossRef
52.
53.
Choi H, Demeke D, Kang FA, Kishi Y, Nakajima K, Nowak P, Wan ZK, Xie C (2003) Pure Appl Chem 75:1–17CrossRef
54.
Austad BC, Benayoud F, Calkins TL, Campagna S, Chase CE, Choi H, Christ W, Costanzo R, Cutter J, Endo A, Fang FG, Hu Y, Lewis BM, Lewis MD, McKenna S, Noland TA, Orr JD, Pesant M, Schnaderbeck MJ, Wilkie GD, Abe T, Asai N, Asai Y, Kayano A, Kimoto Y, Komatsu Y, Kubota M, Kuroda H, Mizuno M, Nakamura T, Omae T, Ozeki N, Suzuki T, Takigawa T, Watanabe T, Yoshizawa K (2013) Synlett 24:327–332CrossRef
55.
56.
Crabtree RH, Felkin H, Fellebeen-Khan T, Morris GE (1979) J Organomet Chem 168:183–195CrossRef
57.
58.
Guo H, Dong CG, Kim DS, Urabe D, Wang J, Kim JT, Liu X, Sasaki T, Kishi Y (2009) J Am Chem Soc 131:15387–15393CrossRef
59.
Liu X, Henderson JA, Sasaki T, Kishi Y (2009) J Am Chem Soc 131:16678–16680CrossRef
60.
61.
Kim DS, Dong CG, Kim JT, Guo H, Huang J, Tiseni PS, Kishi Y (2009) J Am Chem Soc 131:15636–15641CrossRef
62.
63.
Dong CG, Henderson JA, Kaburagi Y, Sasaki T, Kim DS, Kim JT, Urabe D, Guo H, Kishi Y (2009) J Am Chem Soc 131:15642–15646CrossRef
64.
65.
66.
67.
Uguen D (1981) Bull Chim Soc Fr II:99–102
68.
Liu L, Henderson JA, Yamamoto A, Brémond P, Kishi Y (2012) Org Lett 14:2262–2265CrossRef
69.
70.
71.
72.
73.
74.
75.
76.
Blanchette MA, Choy W, Davis JT, Essenfeld AP, Masamune S, Roush WR, Sakai T (1984) Tetrahedron Lett 25:2183–2186CrossRef
77.
78.
Belanger F, Chase CE, Endo A, Fang FG, Li J, Mathieu SR, Wilcoxen AZ, Zhang H (2015) Angew Chem Int Ed 54:5108–5111CrossRef
79.
Liu KKC, Sakya SM, O’Donnell CJ, Flick AC, Ding HX (2012) Bioorg Med Chem 20:1155–1174CrossRef
80.
Chase C, Endo A, Fang FG, Li J (2009) Intermediates and methods for the synthesis of halichondrin B analogs. PCT Int Appl WO 2009/046308, 9 April 2009
81.
Kim D-S, Choi H-W, Chase CE, Lee J (2015) Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin B. PCT Int Appl WO 2015/066729, 7 May 2015
82.
Garber SB, Kingsbury JS, Gray BL, Hoveyda AH (2000) J Am Chem Soc 122:8168–8179CrossRef
83.
Schauer DJ, Helquist P (2006) Synthesis 3654–3660
84.
85.
86.
87.
88.
Narayan S, Carlson EM, Cheng H, Du H, Hu Y, Jiang Y, Lewis BM, Seletsky BM, Tendyke K, Zhang H, Zheng W, Littlefield BA, Towle MJ, Yu MJ (2011) Bioorg Med Chem Lett 21:1630–1633CrossRef
89.
Narayan S, Carlson EM, Cheng H, Condon K, Du H, Eckley S, Hu Y, Jiang Y, Kumar V, Lewis BM, Saxton P, Schuck E, Seletsky BM, Tendyke K, Zhang H, Zheng W, Littlefield BA, Towle MJ, Yu MJ (2011) Bioorg Med Chem Lett 21:1634–1638CrossRef
90.
91.
Narayan S, Carlson EM, Cheng H, Condon K, Du H, Eckley S, Hu Y, Jiang Y, Kumar V, Lewis BM, Saxton P, Schuck E, Seletsky BM, Tendyke K, Zhang H, Zheng W, Littlefield BA, Towle MJ, Yu MJ (2011) Bioorg Med Chem Lett 21:1639–1643CrossRef
92.
93.
Rudolph A, Alberico D, Jordan R, Pan M, Souza FES, Gorin B (2013) Tetrahedron Lett 54:7059–7061CrossRef
94.
95.
96.
Sabitha G, Chandrashekhar G, Yadav JS, Rachineni K, Jagadeesh B (2012) RSC Adv 2:10157–10159CrossRef
97.
98.
99.
Murthy AS, Mahipal B, Chandrasekhar S (2012) Eur J Org Chem 6959–6966
100.
Chandrasekhar S, Yaragorla SR, Sreelakshmi L, Reddy CR (2008) Tetrahedron 64:5174–5183CrossRef
101.
102.
103.
Lavanya N, Kiranmai N, Mainkar PS, Chandrasekhar S (2015) Tetrahedron Lett 56:4283–4285CrossRef
104.
Liu J, Liu Y, Zhang X, Zhang C, Gao Y, Wang L, Du Y (2012) J Org Chem 77:9718–9723CrossRef
105.
106.
107.
108.
Chavan LN, Chegondi R, Chandrasekhar S (2015) Tetrahedron Lett 56:4286–4288CrossRef
109.
Goel S, Mita AC, Mita M, Rowinsky EK, Chu QS, Wong N, Desjardins C, Fang F, Jansen M, Shuster DE, Mani S, Takimoto CH (2009) Clin Cancer Res 15:4207–4212CrossRef
110.
Tan AR, Rubin EH, Walton DC, Shuster DE, Wong NY, Fang F, Ashworth S, Rosen LS (2009) Clin Cancer Res 15:4213–4219CrossRef
111.
Vahdat L, Pruitt B, Fabian CJ, Rivera RR, Smith DA, Tan-Chiu E, Wright J, Tan AR, DaCosta NA, Chuang E, Smith J, O’Shaughnessy J, Shuster DE, Meneses NL, Chandrawansa K, Fang F, Cole PE, Ashworth S, Blum JL (2009) J Clin Oncol 27:2954–2961CrossRef
112.
Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roché H, Bachelot T, Awada A, Pardaens R, Goncalves A, Shuster DE, Wanders J, Fang F, Gurnani R, Richmond E, Cole PE, Ashworth S, Allison MA (2010) J Clin Oncol 28:3922–3928CrossRef
113.
Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikasd A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C (2011) Lancet 377:914–923CrossRef
114.
115.
Gaducci A, Guerrieri ME (2015) Expert Opin Pharmacother 16:335–346
116.
117.
Koczywas M, Frankel PH, Synold TW, Lenz H-J, Mortimer JE, El-Khoueiry AB, Gandara DR, Cristea MC, Chung VM, Lim D, Reckamp KL, Lau DH, Doyle LA, Ruel C, Carroll MI, Newman EM (2014) Br J Cancer 111:2268–2274CrossRef
118.
O’Rourke B, Yang C-PH, Sharp D, Horwitz SB (2014) Cell Cycle 13:3218–3221CrossRef
119.
Yoshida T, Ozawa Y, Kimura T, Sato Y, Kuznetsov G, Xu S, Uesugi M, Agoulnik S, Taylor N, Funahashi Y, Matsui J (2014) Br J Cancer 110:1497–1505CrossRef
120.
Fukuyama T, Chiba H, Takigawa T, Komatsu Y, Kayano A, Tagami K (2016) Org Process Res Dev 20:100–104CrossRef
Metadata
Title
Story of Eribulin Mesylate: Development of the Longest Drug Synthesis
Author
Armin Bauer
Copyright Year
2016
Book
Synthesis of Heterocycles in Contemporary Medicinal Chemistry

Print ISBN: 978-3-319-39915-7

Electronic ISBN: 978-3-319-39917-1

Copyright Year: 2016

DOI
https://doi.org/10.1007/7081_2016_201

Premium Partners

    Image Credits